Depression Screening Market Research Report - Global Forecast till 2027

Depression Screening Market: Information by Disease Type (Anxiety, Mood Disorders, Depression, Bipolar Disorders, Psychotic Disorders and Eating Disorders), Diagnosis (Psychological Test, Lab Tests and Depression Screening Tests) Treatment (Medication, Brain-Stimulation Treatments and Substance Abuse Treatment), End User and Region - Global Forecast till 2027

ID: MRFR/Pharma/2518-CR | July 2019 | Region: Global | 102 pages

Please note that the assessment period of report has been updated from 2018-2023 to 2020-2027. Cordially fill the sample form for updated data.

Depression Screening Market Overview


The increasing problem of mental disorders all over the world and owing to the increase in the use of digital health technologies for mental health acts as s driving force for the growth of the depression screening market in the global market. The changing lifestyle and living standards and the growing use of smoking and the increase in the consumption of alcohol are the main factors that lead to the problem of mental disorder and hence leads to depression. Because of the growing population, and lack of medical experts the depression screening market is touching heights in terms of growth.


Depression is a common disease and it should not be mixed with regular sadness. It is a very dangerous disease as it affects the behaviour of a person. Hence depression test is required and in the technology-driven era, depression screening is done using advanced technology. The depression screening market in the global market is expected to grow at a high CAGR of 6.2% to reach USD 5177.8 million during the forecast period.


COVID 19 Analysis


The global pandemic of COVID 19 has not only affected the physical well-being of individuals, but it affected the psychological aspects also. Prolonged physical distance associated with social isolation, collective grief, the virus itself are some of the major side effects of COVID 19 which everyone has to face and it has put a negative impact on the minds of the people. Because of COVID 19, unemployment has also increased many times which not only affects the financial position but also affects emotionally. These are the few reasons which lead to mental disorders and hence depression.


Owing to the increase in the number of patients, it became necessary for the adoption of an online depression screening test. those who do not feel comfortable visiting doctors can use it from their place only and hence it is expected that the depression screening market will grow in the global market at the beginning of the second quarter of the coming year.


Market Dynamics


Drivers


Owing the increase in the cases of mental disorders and the rise in the adoption of new therapies and treatments using advanced technology are the common factors that drive the growth of the depression screening market in the global market. Also, the World Health Organization has called depression the leading cause of disability across the globe it also drives the growth-share.


Opportunities


The increasing awareness among the people regarding the health issues and its timely screening have boosted the growth of the market. Also, the advancement in technology and its integration with the healthcare sector have helped in the growth of the global market. Because of the frequent suicide cases owing to the global pandemic many governments have taken initiatives regarding regular screening of depression or anxiety tests which is also a big opportunity for the depression screening market in the global market.


Restraints


Although technology is booming in every sector possible still there is lack of awareness of mental disorders and treatments in most of the developing nations hinders the growth of the depression screening market.


Value Chain Analysis


Just like due importance is given to high blood pressure, diabetes, and various other physical disorders, the mental disorder should also be given due importance. That is why the depression screening market is growing at a high rate and screening is just the first step in getting help. Depression is not only a mental sickness but is an issue of major concern as it leads to suicidal tendencies.


With the depression screening market, now one can take free screening so that those who are in doubt regarding the symptoms of depression can get properly evaluated and can get treatment at an early stage.


Market Segmentation


The global market has been divided based on division type, diagnosis, treatment, end-users, and region.


Based on disease type


The global market is divided based on disease type into mood disorders, depression, bipolar disorders, anxiety, psychotic disorders, and eating disorders.


Based on diagnosis


The global market is divided based on diagnosis into psychological tests, lab tests, and depression screening tests.


Based on treatment


The global market is divided based on treatment into medication, brain-stimulation treatments, and substance abuse treatment.


Based on end-users


The global market is divided based on end-users into hospitals and clinics, medical research centers, and academic institutes.


Based on region


The global market is divided based on region into America, Europe, Asia-Pacific, and the Middle East, and Africa.


Regional Analysis


In the global depression screening market, America holds the largest share. Out of which, owing to the availability of advanced diagnostic and treatment methods, an increasing number of patients, and raising funds for research, the North American region dominates the market.


The second-largest market share in the global depression screening method is held by Europe because of the development of healthcare facilities in many countries like Germany, France, and the U.K.


Owing to the fastest-growing region in the global market, Asia-Pacific holds the third position in the global market. Increasing development in countries like India, South Korea, and China in healthcare facilities has increased the demand for the depression screening market.


Competitive Landscape


The major key players in the global depression screening market are as follows:



  • ALLERGAN (Republic of Ireland)

  • Alkermes (Republic of Ireland)

  • AstraZeneca (U.K.)

  • Eli Lily and Company (U.S.)

  • Pfizer Inc. (U.S.)

  • Bristol-Myers Squibb Company (U.S.)

  • Hoffmann-La Roche Ltd (Switzerland)

  • Novartis AG (Switzerland)

  • Johnson and Johnson Services, Inc. (U.S.)


Most of the major key players in the depression screening market in the global market operate using the key strategies of product development, innovation, and acquisitions, and mergers.


Recent Developments



  • In November 2018, a campaign for expanding treatment and screening of depression using technology. This campaign has helped in guiding symptoms of depression and how patients can openly discuss their problems with their doctors for better treatment.

  • In October 2017, a new postpartum depression screening program has been launched under which the new mothers have been monitored after 2 days of giving birth and in that, they have to answer few questions by which the doctor will analyze the symptoms of depression. This program is launched by Cedars-Sinai Medical Centre.

  • In November 2020, Janssen announced its merger with Koa Health, and together they will provide cost-effective digital treatment for depression suffering patients and various therapies to strengthen their position in the global market.

  • In recent times many self-management applications have been developed as a result, it helps in managing stress, anxiety and can have a track of their heart rate, blood pressure, and many other things.

  • Many applications related to improvement in thinking skills have also developed to reduce stress and anxiety from the students. These applications help in monitoring serious mental illness. Not only these many skill-training applications have also developed in the recent past to provide social support.


Report Overview


This global depression screening market research report consists of the following:



  • Market Overview

  • COVID 19 Analysis

  • Market Dynamics

  • Value Chain Analysis

  • Market Segmentation

  • Regional Analysis

  • Competitive Landscape

  • Recent Developments


This report contains various aspects related to the depression screening market along with future estimation, the impact of COVID 19 in increasing depression cases, and opportunities and challenges that the market face.


Research Methodology


Data collection is done using large sample size and various statistical models are used to analyze the market data along with key trend analysis. DBMR research methodology is used in data triangulation that has an analysis of the impact of data variables in the market, data mining, and primary (industry expert) validation. Various primary respondents have been chosen for the sample size like doctors, surgeons, medical players, scientists, promotors, healthcare authorities, insurers, and others.


Users


Pharmaceutical companies, the medical device industry, research, and development organization, academic institutes, diagnostic laboratories, healthcare payers, government institutes, and others.



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2023: USD 5177.8 million
  • 2027: Significant Value
  •   CAGR   6.2% (2018-2023)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Division type, Diagnosis, Treatment, End-users
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   ALLERGAN (Republic of Ireland), Alkermes (Republic of Ireland), AstraZeneca (U.K.), Eli Lily and Company (U.S.), Pfizer Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Johnson and Johnson Services, Inc. (U.S.)
      Key Market Opportunities

  • Increasing awareness among the people regarding the health issues
  • Timely screening
  • Advancement in technology and its integration
  •   Key Market Drivers

  • Increase in the cases of mental disorders
  • Rise in the adoption of new therapies and treatments
  • The leading cause of disability


  • Frequently Asked Questions (FAQ) :


    Depression screening market projected to grow at approximately 6.2% CAGR during the assessment period (2020-2027).

    The valuation of the global depression screening market is estimated to increase to USD 5,177.8 MN by the end of 2023.

    Increasing cases of patients with various mental disorders, changing lifestyle, and rising funding for R&D & clinical trials are major tailwinds pushing the growth of the global depression screening market.

    North America holds the largest share in the global depression screening market, followed by Europe and the Asia Pacific, respectively.

    ALLERGAN (Republic of Ireland), Alkermes (Republic of Ireland), AstraZeneca (UK), Eli Lilly and Company (US), Pfizer Inc. (US), Bristol-Myers Squibb Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Johnson & Johnson Services, Inc. (US), and Otsuka Holdings Co., Ltd. (Japan), are some of the top players operating in the global depression screening market.

    1 Report Prologue

    2 Market Introduction

    2.1 Scope of Study 16

    2.2 Research Objective 16

    2.3 Assumptions & Limitations 16

    2.3.1 Assumptions 16

    2.3.2 Limitations 16

    3 Research Methodology

    3.1 Primary Research Methodology 18

    3.2 Secondary Research Methodology 19

    3.3 Market Share Analysis 20

    3.4 Trade Analysis 20

    3.5 Market Pricing Approach 20

    4 Market Dynamics

    4.1 Introduction 21

    4.2 Drivers 22

    4.2.1 Emergence of Digital Health Technologies in Mental Health (Impact Weightage-45%) 22

    4.2.2 Growing Prevalence of Mental Disorders Around the Globe (Impact Weightage-30%) 23

    4.2.3 New Focus Areas in the Care Continuum are Prevention and Recovery (Impact Weightage-25%) 24

    4.3 Restraints 25

    4.3.1 Low Public Awareness of Mental Disorders and Treatments in Emerging Nations (Impact Weightage-55%) 25

    4.3.2 Cultural Stigma Preventing the Market Growth (Impact Weightage-45%) 26

    5 Market Factor Analysis

    5.1 Porter’s Five Forces Model 27

    5.1.1 Bargaining Power of Suppliers 28

    5.1.2 Bargaining Power of Buyers 28

    5.1.3 Threat of New Entrants 28

    5.1.4 Threat of Substitutes 28

    5.1.5 Intensity of Rivalry 28

    5.2 Value Chain Analysis 29

    6 Depression Screening Market, By Disease Type

    6.1 Introduction 30

    6.2 Anxiety 32

    6.3 Mood Disorders 32

    6.4 Depression 33

    6.5 Bipolar Disorders 33

    6.6 Psychotic Disorders 34

    6.7 Eating Disorders 34

    7 Depression Screening Market, By Diagnosis

    7.1 Introduction 35

    7.2 Psychological Test 36

    7.3 Lab Tests 37

    7.4 Depression Screening Tests 37

    8 Depression Screening Market, By Treatment

    8.1 Introduction 38

    8.2 Medication 40

    8.3 Brain-Stimulation Treatments 40

    8.4 Substance Abuse Treatment 41

    9 Depression Screening Market, By End User

    9.1 Introduction 42

    9.2 Hospitals & Clinics 43

    9.3 Medical Research Centers 43

    9.4 Academic Institutes 44

    10 Global Depression Screening Market, By Region

    10.1 Introduction 45

    10.2 Americas 46

    Depression Screening Market, By Disease Type

    Depression Screening Market, By Diagnosis

    Depression Screening Market, By Treatment

    Depression Screening Market, By End User

    10.2.1 US …………………………………………………………………………………………………49

    Depression Screening Market, By Disease Type

    Depression Screening Market, By Diagnosis

    Depression Screening Market, By Treatment

    Depression Screening Market, By End User

    10.2.2 Canada 51

    Depression Screening Market, By Disease Type

    Depression Screening Market, By Diagnosis

    Depression Screening Market, By Treatment

    Depression Screening Market, By End User

    10.2.3 South America 53

    Depression Screening Market, By Disease Type

    Depression Screening Market, By Diagnosis

    Depression Screening Market, By Treatment

    Depression Screening Market, By End User

    10.3 Europe 55

    Depression Screening Market, By Disease Type

    Depression Screening Market, By Diagnosis

    Depression Screening Market, By Treatment

    Depression Screening Market, By End User

    10.3.1 Germany 58

    Depression Screening Market, By Disease Type

    Depression Screening Market, By Diagnosis

    Depression Screening Market, By Treatment

    Depression Screening Market, By End User

    10.3.2 France 60

    Depression Screening Market, By Disease Type

    Depression Screening Market, By Diagnosis

    Depression Screening Market, By Treatment

    Depression Screening Market, By End User

    10.3.3 UK 62

    Depression Screening Market, By Disease Type

    Depression Screening Market, By Diagnosis

    Depression Screening Market, By Treatment

    Depression Screening Market, By End User

    10.3.4 Italy 64

    Depression Screening Market, By Disease Type

    Depression Screening Market, By Diagnosis

    Depression Screening Market, By Treatment

    Depression Screening Market, By End User

    10.3.5 Spain 66

    Depression Screening Market, By Disease Type

    Depression Screening Market, By Diagnosis

    Depression Screening Market, By Treatment

    Depression Screening Market, By End User

    10.3.6 Rest of Western Europe 68

    Depression Screening Market, By Disease Type

    Depression Screening Market, By Diagnosis

    Depression Screening Market, By Treatment

    Depression Screening Market, By End User

    10.3.7 Eastern Europe 70

    Depression Screening Market, By Disease Type

    Depression Screening Market, By Diagnosis

    Depression Screening Market, By Treatment

    Depression Screening Market, By End User

    10.4 Asia-Pacific 72

    Depression Screening Market, By Disease Type

    Depression Screening Market, By Diagnosis

    Depression Screening Market, By Treatment

    Depression Screening Market, By End User

    10.4.1 Japan 75

    Depression Screening Market, By Disease Type

    Depression Screening Market, By Diagnosis

    Depression Screening Market, By Treatment

    Depression Screening Market, By End User

    10.4.2 China 77

    Depression Screening Market, By Disease Type

    Depression Screening Market, By Diagnosis

    Depression Screening Market, By Treatment

    Depression Screening Market, By End User

    10.4.3 India 79

    Depression Screening Market, By Disease Type

    Depression Screening Market, By Diagnosis

    Depression Screening Market, By Treatment

    Depression Screening Market, By End User

    10.4.4 Australia 81

    Depression Screening Market, By Disease Type

    Depression Screening Market, By Diagnosis

    Depression Screening Market, By Treatment

    Depression Screening Market, By End User

    10.4.5 South Korea 83

    Depression Screening Market, By Disease Type

    Depression Screening Market, By Diagnosis

    Depression Screening Market, By Treatment

    Depression Screening Market, By End User

    10.4.6 Rest of Asia-Pacific 85

    Depression Screening Market, By Disease Type

    Depression Screening Market, By Diagnosis

    Depression Screening Market, By Treatment

    Depression Screening Market, By End User

    10.5 Middle East & Africa 87

    Depression Screening Market, By Disease Type

    Depression Screening Market, By Diagnosis

    Depression Screening Market, By Treatment

    Depression Screening Market, By End User

    10.5.1 Middle East 90

    Depression Screening Market, By Disease Type

    Depression Screening Market, By Diagnosis

    Depression Screening Market, By Treatment

    Depression Screening Market, By End User

    10.5.2 Africa 92

    Depression Screening Market, By Disease Type

    Depression Screening Market, By Diagnosis

    Depression Screening Market, By Treatment

    Depression Screening Market, By End User

    11 Company Share Analysis

    12 Company Profiles: Top 7 Players

    12.1 Allergan 95

    12.1.1 Company Overview 95

    12.1.2 Financials 95

    12.1.3 Products 95

    12.1.4 Strategy 95

    12.1.5 Key Developments 95

    12.2 Eli Lilly 96

    12.2.1 Company Overview 96

    12.2.2 Financials 96

    12.2.3 Products 96

    12.2.4 Strategy 96

    12.2.5 Key Developments 96

    12.3 Novartis AG 97

    12.3.1 Company Overview 97

    12.3.2 Financials 97

    12.3.3 Products 97

    12.3.4 Strategy 97

    12.3.5 Key Developments 97

    12.4 Alkermes 98

    12.4.1 Company Overview 98

    12.4.2 Financials 98

    12.4.3 Products 98

    12.4.4 Strategy 98

    12.4.5 Key Developments 98

    12.5 Bristol-Myers Squibb Company 99

    12.5.1 Company Overview 99

    12.5.2 Financials 99

    12.5.3 Products 99

    12.5.4 Strategy 99

    12.5.5 Key Developments 99

    12.6 Pfizer 100

    12.6.1 Company Overview 100

    12.6.2 Financials 100

    12.6.3 Products 100

    12.6.4 Strategy 100

    12.6.5 Key Developments 100

    12.7 AstraZeneca 101

    12.7.1 Company Overview 101

    12.7.2 Financials 101

    12.7.3 Products 101

    12.7.4 Srategy 101

    12.7.5 Key Developments 101

    13 List of Tables

    TABLE 1 PRIMARY INTERVIEWS 18

    TABLE 2 GLOBAL DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 31

    TABLE 3 GLOBAL DEPRESSION SCREENING MARKET FOR ANXIETY, BY REGION, 2020–2027 (USD MILLION) 32

    TABLE 4 GLOBAL DEPRESSION SCREENING MARKET FOR MOOD DISORDERS, BY REGION,

    2020–2027 (USD MILLION) 32

    TABLE 5 GLOBAL DEPRESSION SCREENING MARKET FOR DEPRESSION, BY REGION, 2020–2027 (USD MILLION) 33

    TABLE 6 GLOBAL DEPRESSION SCREENING MARKET FOR BIPOLAR DISORDERS, BY REGION,

    2020–2027 (USD MILLION) 33

    TABLE 7 GLOBAL DEPRESSION SCREENING MARKET FOR PSYCHOTIC DISORDERS, BY REGION,

    2020–2027 (USD MILLION) 34

    TABLE 8 GLOBAL DEPRESSION SCREENING MARKET FOR EATING DISORDERS, BY REGION,

    2020–2027 (USD MILLION) 34

    TABLE 9 GLOBAL DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 35

    TABLE 10 GLOBAL DEPRESSION SCREENING MARKET FOR PSYCHOLOGICAL TEST, BY REGION,

    2020–2027 (USD MILLION) 36

    TABLE 11 GLOBAL DEPRESSION SCREENING MARKET FOR LAB TESTS, BY REGION, 2020–2027 (USD MILLION) 37

    TABLE 12 GLOBAL DEPRESSION SCREENING MARKET FOR DEPRESSION SCREENING TESTS, BY REGION,

    2020–2027 (USD MILLION) 37

    TABLE 13 GLOBAL DEPRESSION SCREENING MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 39

    TABLE 14 GLOBAL DEPRESSION SCREENING MARKET FOR MEDICATION, BY REGION, 2020–2027 (USD MILLION) 40

    TABLE 15 GLOBAL DEPRESSION SCREENING MARKET FOR BRAIN–STIMULATION TREATMENTS, BY REGION,

    2020–2027 (USD MILLION) 40

    TABLE 16 GLOBAL DEPRESSION SCREENING MARKET FOR SUBSTANCE ABUSE TREATMENT, BY REGION,

    2020–2027 (USD MILLION) 41

    TABLE 17 GLOBAL DEPRESSION SCREENING MARKET, BY END USER, 2020–2027 (USD MILLION) 42

    TABLE 18 GLOBAL DEPRESSION SCREENING MARKET FOR HOSPITALS & CLINICS, BY REGION,

    2020–2027 (USD MILLION) 43

    TABLE 19 GLOBAL DEPRESSION SCREENING MARKET FOR MEDICAL RESEARCH CENTERS, BY REGION,

    2020–2027 (USD MILLION) 43

    TABLE 20 GLOBAL DEPRESSION SCREENING MARKET FOR ACADEMIC INSTITUTES, BY REGION,

    2020–2027 (USD MILLION) 44

    TABLE 21 GLOBAL DEPRESSION SCREENING MARKET, BY REGION, 2020–2027 (USD MILLION) 45

    TABLE 22 AMERICAS DEPRESSION SCREENING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 46

    TABLE 23 AMERICAS DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 47

    TABLE 24 AMERICAS DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 47

    TABLE 25 AMERICAS DEPRESSION SCREENING MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 48

    TABLE 26 AMERICAS DEPRESSION SCREENING MARKET, BY END USER, 2020–2027 (USD MILLION) 48

    TABLE 27 US DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 49

    TABLE 28 US DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 49

    TABLE 29 US DEPRESSION SCREENING MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 50

    TABLE 30 US DEPRESSION SCREENING MARKET, BY END USER, 2020–2027 (USD MILLION) 50

    TABLE 31 CANADA DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 51

    TABLE 32 CANADA DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 51

    TABLE 33 CANADA DEPRESSION SCREENING MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 52

    TABLE 34 CANADA DEPRESSION SCREENING MARKET, BY END USER, 2020–2027 (USD MILLION) 52

    TABLE 35 SOUTH AMERICA DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 53

    TABLE 36 SOUTH AMERICA DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 53

    TABLE 37 SOUTH AMERICA DEPRESSION SCREENING MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 54

    TABLE 38 SOUTH AMERICA DEPRESSION SCREENING MARKET, BY END USER, 2020–2027 (USD MILLION) 54

    TABLE 39 EUROPE DEPRESSION SCREENING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 55

    TABLE 40 EUROPE DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 56

    TABLE 41 EUROPE DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 56

    TABLE 42 EUROPE DEPRESSION SCREENING MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 57

    TABLE 43 EUROPE DEPRESSION SCREENING MARKET, BY END USER, 2020–2027 (USD MILLION) 57

    TABLE 44 GERMANY DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 58

    TABLE 45 GERMANY DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 58

    TABLE 46 GERMANY DEPRESSION SCREENING MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 59

    TABLE 47 GERMANY DEPRESSION SCREENING MARKET, BY END USER, 2020–2027 (USD MILLION) 59

    TABLE 48 FRANCE DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 60

    TABLE 49 FRANCE DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 60

    TABLE 50 FRANCE DEPRESSION SCREENING MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 61

    TABLE 51 FRANCE DEPRESSION SCREENING MARKET, BY END USER, 2020–2027 (USD MILLION) 61

    TABLE 52 UK DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 62

    TABLE 53 UK DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 62

    TABLE 54 UK DEPRESSION SCREENING MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 63

    TABLE 55 UK DEPRESSION SCREENING MARKET, BY END USER, 2020–2027 (USD MILLION) 63

    TABLE 56 ITALY DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 64

    TABLE 57 ITALY DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 64

    TABLE 58 ITALY DEPRESSION SCREENING MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 65

    TABLE 59 ITALY DEPRESSION SCREENING MARKET, BY END USER, 2020–2027 (USD MILLION) 65

    TABLE 60 SPAIN DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 66

    TABLE 61 SPAIN DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 66

    TABLE 62 SPAIN DEPRESSION SCREENING MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 67

    TABLE 63 SPAIN DEPRESSION SCREENING MARKET, BY END USER, 2020–2027 (USD MILLION) 67

    TABLE 64 REST OF WESTERN EUROPE DEPRESSION SCREENING MARKET, BY DISEASE TYPE,

    2020–2027 (USD MILLION) 68

    TABLE 65 REST OF WESTERN EUROPE DEPRESSION SCREENING MARKET, BY DIAGNOSIS,

    2020–2027 (USD MILLION) 68

    TABLE 66 REST OF WESTERN EUROPE DEPRESSION SCREENING MARKET, BY TREATMENT,

    2020–2027 (USD MILLION) 69

    TABLE 67 REST OF WESTERN EUROPE DEPRESSION SCREENING MARKET, BY END USER,

    2020–2027 (USD MILLION) 69

    TABLE 68 EASTERN EUROPE DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 70

    TABLE 69 EASTERN EUROPE DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 70

    TABLE 70 EASTERN EUROPE DEPRESSION SCREENING MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 71

    TABLE 71 EASTERN EUROPE DEPRESSION SCREENING MARKET, BY END USER, 2020–2027 (USD MILLION) 71

    TABLE 72 ASIA-PACIFIC DEPRESSION SCREENING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 72

    TABLE 73 ASIA-PACIFIC DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 73

    TABLE 74 ASIA-PACIFIC DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 73

    TABLE 75 ASIA-PACIFIC DEPRESSION SCREENING MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 74

    TABLE 76 ASIA-PACIFIC DEPRESSION SCREENING MARKET, BY END USER, 2020–2027 (USD MILLION) 74

    TABLE 77 JAPAN DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 75

    TABLE 78 JAPAN DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 75

    TABLE 79 JAPAN DEPRESSION SCREENING MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 76

    TABLE 80 JAPAN DEPRESSION SCREENING MARKET, BY END USER, 2020–2027 (USD MILLION) 76

    TABLE 81 CHINA DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 77

    TABLE 82 CHINA DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 77

    TABLE 83 CHINA DEPRESSION SCREENING MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 78

    TABLE 84 CHINA DEPRESSION SCREENING MARKET, BY END USER, 2020–2027 (USD MILLION) 78

    TABLE 85 INDIA DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 79

    TABLE 86 INDIA DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 79

    TABLE 87 INDIA DEPRESSION SCREENING MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 80

    TABLE 88 INDIA DEPRESSION SCREENING MARKET, BY END USER, 2020–2027 (USD MILLION) 80

    TABLE 89 AUSTRALIA DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 81

    TABLE 90 AUSTRALIA DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 81

    TABLE 91 AUSTRALIA DEPRESSION SCREENING MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 82

    TABLE 92 AUSTRALIA DEPRESSION SCREENING MARKET, BY END USER, 2020–2027 (USD MILLION) 82

    TABLE 93 SOUTH KOREA DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 83

    TABLE 94 SOUTH KOREA DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 83

    TABLE 95 SOUTH KOREA DEPRESSION SCREENING MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 84

    TABLE 96 SOUTH KOREA DEPRESSION SCREENING MARKET, BY END USER, 2020–2027 (USD MILLION) 84

    TABLE 97 REST OF ASIA-PACIFIC DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 85

    TABLE 98 REST OF ASIA-PACIFIC DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 85

    TABLE 99 REST OF ASIA-PACIFIC DEPRESSION SCREENING MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 86

    TABLE 100 REST OF ASIA-PACIFIC DEPRESSION SCREENING MARKET, BY END USER, 2020–2027 (USD MILLION) 86

    TABLE 101 MIDDLE EAST & AFRICA DEPRESSION SCREENING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 87

    TABLE 102 MIDDLE EAST & AFRICA DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 88

    TABLE 103 MIDDLE EAST & AFRICA DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 88

    TABLE 104 MIDDLE EAST & AFRICA DEPRESSION SCREENING MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 89

    TABLE 105 MIDDLE EAST & AFRICA DEPRESSION SCREENING MARKET, BY END USER, 2020–2027 (USD MILLION) 89

    TABLE 106 MIDDLE EAST DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 90

    TABLE 107 MIDDLE EAST DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 90

    TABLE 108 MIDDLE EAST DEPRESSION SCREENING MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 91

    TABLE 109 MIDDLE EAST DEPRESSION SCREENING MARKET, BY END USER, 2020–2027 (USD MILLION) 91

    TABLE 110 AFRICA DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 92

    TABLE 111 AFRICA DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 92

    TABLE 112 AFRICA DEPRESSION SCREENING MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 93

    TABLE 113 AFRICA DEPRESSION SCREENING MARKET, BY END USER, 2020–2027 (USD MILLION) 93

    14 List of Figures

    FIGURE 1 GLOBAL DEPRESSION SCREENING MARKET SHARE, BY DISEASE TYPE 2020 (%) 13

    FIGURE 2 GLOBAL DEPRESSION SCREENING MARKET SHARE, BY DIAGNOSIS, 2020 (%) 13

    FIGURE 3 GLOBAL DEPRESSION SCREENING MARKET SHARE, BY TREATMENT, 2020 (%) 14

    FIGURE 4 GLOBAL DEPRESSION SCREENING MARKET, BY REGION, 2020 (%) 15

    FIGURE 5 RESEARCH METHODOLOGY 17

    FIGURE 6 PORTERS FIVE FORCES MODEL 27

    FIGURE 7 VALUE CHAIN: DEPRESSION SCREENING MARKET 29

    FIGURE 8 GLOBAL DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2020 & 2027 (USD MILLION) 31

    FIGURE 9 GLOBAL DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2020 & 2027 (USD MILLION) 36

    FIGURE 10 GLOBAL DEPRESSION SCREENING MARKET, BY TREATMENT, 2020 & 2027 (USD MILLION) 39

    FIGURE 11 GLOBAL DEPRESSION SCREENING MARKET, BY END USER, 2020 & 2027 (USD MILLION) 42

    FIGURE 12 AMERICAS DEPRESSION SCREENING MARKET, BY COUNTRY, 2020 (%) 46

    FIGURE 13 EUROPE DEPRESSION SCREENING MARKET, BY COUNTRY, 2020 (%) 55

    FIGURE 14 ASIA-PACIFIC DEPRESSION SCREENING MARKET, BY COUNTRY, 2020 (%) 72

    FIGURE 15 MIDDLE EAST & AFRICA DEPRESSION SCREENING MARKET, BY COUNTRY, 2020 (%) 87

    FIGURE 16 GLOBAL DERESSION SCREENING MARKET: COMPANY SHARE ANALYSIS 94